fda decision on compounded tirzepatide Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro Update from Big Easy on
Description
Platos allegory of the cave by Jan Saenredam, according to Cornelis van Haarlem, 1604, Albertina, Vienna B-C
doi: 10.1016/j.fertnstert.2023.08.635
Developed by Eli Lilly under the research designation LY3437943, retatrutide is currently investigational and undergoing Phase 3 clinical trials
Treatment discontinuation: 32.1 percent (Trulicity) versus 49.4 percent (exenatide)
Ozempic for Type 2 diabetes is generally covered with prior authorization
